Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06187376
Other study ID # STUDY-23-01101
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 2024
Est. completion date July 2025

Study information

Verified date May 2024
Source Icahn School of Medicine at Mount Sinai
Contact Nicola Tavella, MPH
Phone (212) 241-3888
Email nicola.tavella@mssm.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective randomized-controlled trial looking at the safety and acceptability of using Chinese herbal medicine in patients with primary dysmenorrhea. The research team hopes to enroll 100 patients, 50 of whom will be randomized to receive the herbal tincture and 50 who will receive a placebo tincture. Patients will be enrolled and using the assigned tincture for twelve weeks. The research team will assess safety as a primary outcome by the presence or absence of adverse events related to study protocol during the period of participation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date July 2025
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 36 Years
Eligibility Inclusion Criteria: - Female aged 18-36 are met: - Self-reported pain or discomfort during menstruation, as indicated by Grade 1 or higher on the verbal multidimensional scoring system - May experience regular menstrual cycle and period must be <7 days in duration - May be on birth control - Must know or can estimate the date of the next cycle/period - May find blood clots in menstrual blood - Must be in good health (doesn't report any medical conditions asked in the screening questionnaire) - Following a stable, consistent diet regimen - Follow a stable, consistent exercise regimen and are willing, for the duration of the study, to not decrease or increase the amount of exercise in their regimen - Agree to refrain from any lifestyle changes that may affect their menstrual cycle for the duration of the study (for example, getting on or off hormonal birth control, reducing the amount of exercise) - Follow a stable consistent regimen when using any other interventions, such as massage, chiropractic medicine, or acupuncture; agree not to increase or decrease the number of their other interventions - Willingness to adhere to the dietary supplement regimen - Willingness to refrain from any other dietary supplements targeting the menstrual cycle during the study period - Is able to communicate in English - Is willing and able to share feedback via REDCap - Must provide written informed consent (ICF) Exclusion Criteria: - Do not experience a menstrual cycle - Cannot estimate the onset of their next menstrual cycle - Do not experience menstrual pain or cramping - Follow an extreme diet intervention - Experienced severe weight loss in the past 3 months prior to study participation - If currently taking allowed supplements, the dosage needs to remain the same throughout the entirety of the study - Food intolerances/allergies that require an EpiPen - Known allergic reaction to any of the test product ingredients - Currently pregnant, want to become pregnant for the duration of the study, or who are breastfeeding - Previous users of Elix Cycle Balance - Having more than 3 alcoholic drinks a day - Have been diagnosed with the following conditions: PCOS, endometriosis, PMDD, adenomyosis, Hashimoto's, anorexia, bulimia, orthorexia, binge eating, any other eating disorder - Smokers - Not been on a stable dose of birth control for the past 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chinese Herbal Medicine (CHM) supplement
Dropper of tincture by mouth for 12 weeks.
Placebo
Matching placebo tincture.

Locations

Country Name City State
United States Mount Sinai Faculty Practice Associates New York New York

Sponsors (2)

Lead Sponsor Collaborator
Icahn School of Medicine at Mount Sinai Zenchi, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Presence or absence of any adverse events Presence or absence of any adverse events related to the study protocol during the time of participation. up to 3 months
Secondary Dysmenorrhea Symptom Interference (DSI) Scale Dysmenorrhea Symptom Interference (DSI) Scale: Is a nine-item validated measure of symptoms associated with dysmenorrhea including working ability, location, intensity, and days of pain. Symptoms are ranked from 1 (not at all) to 5 (very much) with regard to their interference with various aspects of their daily function. To generate total scores, the nine-items are averaged, thus total scale scores range from 1-5, with higher scores indicating greater interference of dysmenorrhea symptoms. up to 3 months
See also
  Status Clinical Trial Phase
Completed NCT04607382 - Survey on Menstrual Symptoms, Health Related Quality of Life and Work Productivity in Patients Suffering From Pain During Menstruation (Dysmenorrhea) in Japan
Recruiting NCT04091789 - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea Phase 2
Completed NCT00769964 - VA111913 TS: First in Human Study Phase 1
Completed NCT00746096 - Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea Phase 3
Completed NCT00104546 - Vitamin K Injections for the Treatment of Painful Menstruation Phase 1
Completed NCT06011928 - MOPEXE and RE in Treating Dysmenorrhea N/A
Not yet recruiting NCT06398990 - The Effect of Cognitive Exercise Therapy Approach and Yoga in Adolescents With Dysmenorrhoea N/A
Recruiting NCT02031523 - Multi-center Clinical Trials of Sanjie Analgesic Capsule in Treating Endometriosis Phase 4
Completed NCT01449305 - Effectiveness of Nanoone Woman Underwear Using in the Management of Dysmenorrhea N/A
Completed NCT00995917 - A Pilot Study of Acupoint Injection for Primary Dysmenorrhea N/A
Completed NCT02910167 - Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima
Not yet recruiting NCT05461846 - Effect of Integrated Neuromuscular Inhibition Technique in Females With Menstrual Low Back Pain N/A
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Not yet recruiting NCT03697746 - Comparison of Dexketoprofen, Paracetamol and Ibuprofen in the Treatment of Primary Dysmenorrhea N/A
Recruiting NCT03394547 - Pulsed Electromagnetic Field Treatment for Painful Periods N/A
Recruiting NCT06294743 - Posterior Tibia Nerve Neuroprolotherapy for Dysmenorrhea Early Phase 1
Active, not recruiting NCT01738204 - The Women's Health Study: From Adolescence to Adulthood
Completed NCT01462370 - Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1) Phase 3
Completed NCT01250587 - Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea Phase 1
Completed NCT00951561 - A Comparison Study of Pain Relief From Dysmenorrhea Between the Vipon Tampon and Ibuprofen N/A